专利检索 ap:("Viracta Therapeutics, Inc.") AND inv:"Minke E. BINNERTS" 第 1 页

1.

发明申请
HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER 有权

公开(公告)号：US20230099829A1

公开(公告)日：2023-03-30

申请号：US17831041

申请日：2022-06-02

申请人： Viracta Therapeutics, Inc.

发明人： Stig K. HANSEN , Minke E. BINNERTS

IPC分类号： A61K31/497 , A61K31/506 , A61K31/444 , A61K31/4439 , A61K31/519 , A61K31/517 , A61P35/02

摘要： Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.

2.

发明公开
HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER 审中-公开

公开(公告)号：US20240207258A1

公开(公告)日：2024-06-27

申请号：US18600974

申请日：2024-03-11

申请人： Viracta Therapeutics, Inc.

发明人： Stig K. HANSEN , Minke E. BINNERTS

IPC分类号： A61K31/497 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/517 , A61K31/519 , A61P35/02

CPC分类号： A61K31/497 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/517 , A61K31/519 , A61P35/02

摘要： Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.